MEMOIR, Digital Insulin Pen

Eli Lilly and Company announces the launch of the first insulin pen with memory, HumaPen MEMOIR, to help simplify the daily management of diabetes.

MEMOIR is designed to meet the needs of people with diabetes who take several shots of mealtime insulin each day. It presents sophisticated technology in a consumer-friendly, "push-to-know" digital display, allowing patients to record and review their last 16 insulin doses, including the priming doses.

The ability to record doses and the time of the dose may help simplify the daily management of diabetes, which is especially important for both patients and physicians when developing a diabetes treatment plan that utilizes accurate recording of mealtime doses. MEMOIR is now available by prescription in pharmacies nationwide for use with Humalog (insulin lispro injection [rDNA origin]), the most-prescribed mealtime insulin in the United States.

Unlike traditional insulin pens, or vial and syringe, MEMOIR doesn't resemble a medical instrument. MEMOIR, which is reusable, is sleek and designed to resemble a writing pen, enabling the potential for discreet injections in public.

"Individuals with diabetes face unique challenges in managing this highly complex and personal disease. Practical and innovative solutions such as Lilly's new MEMOIR pen can help ease the management of diabetes at mealtimes," said Matt Beebe, Humalog brand team leader, Lilly USA. "Our goal is to help patients more accurately and discreetly manage their use of mealtime insulin such as Humalog."